AbbVie reported an 86.6% as-observed clinical remission rate at week 144 among Crohn’s disease patients taking upadacitinib 30 mg, while separate ulcerative colitis data showed rates up to 73.1% at week 96. The company plans to present the findings during United European Gastroenterology Week, held Oct. 17-20 in Barcelona and online.
At week 96 in COMMAND, the company put clinical remission with risankizumab (Skyrizi) 180 mg between 54.0% and 73.1% across groups with and without prior advanced therapy exposure. Endoscopic remission across those groups ranged from 38.8% to 53.5%.
In the U-ENDURE extension study of Crohn’s disease, AbbVie reported clinical remission rates of 78.9% with upadacitinib (Rinvoq) 15 mg and 86.6% with 30 mg at week 144. The corresponding endoscopic rates were 47.1% with 15 mg and 64.2% with 30 mg. The results come from separate studies of different medicines and conditions, so they do not directly compare the treatments.
Interim UPlift data showed that 70.2% of 497 evaluable patients with moderate-to-severe Crohn’s disease had a clinical response by week 12. The median time before a first response was 13 days.
AbbVie also reported findings from a propensity-score-matched claims analysis of 514 patients with ulcerative colitis or Crohn’s disease. Over 12 months, IBD-related hospitalization rates were 9.5% among patients who changed from a tumor necrosis factor (TNF) inhibitor to upadacitinib and 16.3% among those who changed to another TNF inhibitor. Surgery rates were 6.9% and 10.6%, respectively.
The EMA says adults with moderately to severely active Crohn’s disease or ulcerative colitis may receive either drug after an earlier treatment fails, stops working or causes intolerance. The EMA identifies serious infections as Rinvoq’s most common serious side effect. It says the medicine should be used only when no suitable alternative is available for patients 65 or older, those with certain cardiovascular risks or people at increased cancer risk.
AbbVie said its 20 IBD abstracts will also include data on investigational dual-targeting therapy ABBV-466 in Crohn’s disease. UEG’s program lists the U-ENDURE presentation for Monday, Oct. 19, from 5:30 to 6:30 a.m. ET (09:30 to 10:30 UTC).
